"The UK DRI is a global leader in dementia research and my team and I are delighted to be a part of it, helping to make dementia a thing of the past." Karen Duff
UK DRI Centre Director
Prof Karen Duff is a leader in the field of neurodegenerative disease having first started her career as a PhD student in the Cambridge department of Nobel Prize winner Sydney Brenner. Prof Duff has worked for over 30 years on Alzheimer’s disease and the tauopathies, for which she was awarded the prestigious Potamkin Prize in 2006. Her interests span a range of research areas, from discovery science through to therapeutic approaches. Over her career she has created several important mouse models for AD and FTD-tau and she has studied several disease-associated molecular mechanisms using innovative and state of the art methods. Her most recent interests include the causes and consequences of tau pathology propagation, and the basis of selective cellular vulnerability. Prof Duff recently left Columbia University in New York and has joined the UK DRI at UCL as Centre Director, leading a dynamic and ambitious programme of multidisciplinary and clinically-orientated research.
1. At a glance
Alzheimer’s disease is characterised by the accumulation of protein clumps in the brain, a loss of neurons and memory decline. Over the past decade, it has emerged that one of these harmful proteins, tau, spreads across the brain from neuron to neuron, in a predictable pattern as the disease progresses. Previous research from Prof Karen Duff and her team has explored this phenomenon in great detail. As part of her new programme at UK DRI and using a series of sophisticated methods, she hopes to find ways in which to stop this spreading and slow disease development.
The Duff lab additionally aims to investigate other key questions in dementia research including
why the accumulation of abnormal tau protein leads to many different types of disease, why certain neurons are more vulnerable than others to the harmful effects of tau, how we can help to clear these proteins out of the brain and whether genetic risk factors can give us greater insight into the biological mechanisms behind Alzheimer’s disease and Frontotemporal dementia-tau. It is the hope that deeper understanding in these research areas will drive the development of therapeutics for people living with dementia.
Read an interview with Prof Karen Duff about her work on the protein tau and the phenomenon of selective vulnerability
2. Scientific goals
Causes and consequences of tau pathology propagation
Intraneuronal neurofibrillary tangles (NFTs), consisting of hyperphosphorylated tau protein, are a hallmark of several neurodegenerative conditions including Alzheimer’s disease (AD) and Frontotemporal dementia (FTD). The accumulation of abnormal (argyrophilic) tau starts in the transentorhinal cortex in the earliest stages of AD and spreads through the limbic and association cortices via the trisynaptic circuit in a precise and defined manner, correlating with the cognitive deficits that develop in the condition.
To better understand the causes and consequences of abnormal tau accumulation and the propagation of tauopathy, Prof Duff’s team has used a plethora of methods, and cell and animal models, including a novel transgenic mouse that differentially expresses pathological human tau in the entorhinal cortex (EC-Tau).
The team has published the following key findings:
- Tau spreads from one cell to another transynaptically
- Tau can be internalised both at the somatodendritic and axonal compartments and it can undergo anterograde and retrograde transport
- Modulating neuronal activity by optogenetic or chemogenetic approaches in vivo impacts tauopathy spread
- The accumulation and spread of pathological tau in vivo is associated with neuronal death and tissue atrophy as assessed by MRI, network imbalance and grid field destabilisation assessed by in vivo electrophysiology, and cognitive decline
In her UK DRI programme, Prof Karen Duff plans to build on these insights using sophisticated multi-chamber microfluidic devices, high-end microscopy (optical imaging, single particle cryo EM, EM tomography and immuno electron microscopy), in vivo electrophysiology and, in collaboration, cognitive testing based on virtual reality. These studies have three goals:
1. To identify the key components and mechanisms of tau spread in vitro and in vivo
2. To integrate mouse and cell data with human studies and elucidate the functional consequences of propagating tau pathology
3. To identify and test novel therapeutic targets that will prevent tau from damaging neurons and ameliorate cognitive decline
Causes and consequences of selective cellular vulnerability
A major question that exists across neurodegenerative disease research is why some cells are more vulnerable to pathology than others. To start to define the molecular basis of selective cellular vulnerability, Prof Duff’s published work has demonstrated that tau accumulates in particular neuronal subpopulations, and, using a bioinformatics approach, that these neurons show reduced capacity for tau homeostasis. A major focus of the UK DRI lab will be to extend these studies in human and mouse model tissue using single cell and spatial transcriptomics and proteomics approaches, coupled with bioinformatics.
Genetic modifiers and risk factors
Affected individuals with any neurodegenerative disease show differences in age at onset, severity and rate of progression, and some, such as the tauopathies, show significant clinical diversity in how the disease manifests. In familial cases, diversity can be seen even between closely related affected family members. One objective of the lab to be undertaken in collaboration with MRC Harwell and The Jackson labs, is to identify genetic determinants that impact these outcomes in genetically defined mice, and compare results to human genetic modifiers identified within the UK DRI. An additional aspect of this project is to look at known genetic risk factors, for example ApoE and TRIM1, to determine their role in disease.
One of the key events that leads to a degenerative disease taking hold in the brain is the failure of cells under threat to remove or clear abnormal proteins that are accumulate. The Duff lab has an interest in proteinopathy and failure of the two clearance mechanisms mediated by ubiquitin-proteasome system (UPS) and macroautophagy. One of the objectives of the lab is to identify novel therapeutics that can enhance the clearance of abnormal proteins which may have benefits at the early stages of disease.
3. Team members
Dr Mathieu Bourdenx (Senior Researcher)
Dr Martha Foiani (Postdoctoral Researcher)
Dr Eliona Tsefou (Postdoctoral Researcher)
Dr Naoto Watamura (Postdoctoral Researcher)
Dr Nathasia Muwanigwa (Postdoctoral Researcher)
Samantha Henry (Executive Assistant)
Sumi Bez (PhD Student)
Emir Turkes (PhD Student)
Saisha Patel (PhD Student)
Raquel Taddei (PhD Student)
Izzie Prankerd (PhD Student)
Paula Cauhy (PhD Student)
Tim Birkle (Research Assistant)
James Scott-Solache (Research Assistant)
Xheni Prebibaj (Data Scientist)
Within UK DRI:
- UK DRI Synapse theme - an UK DRI-wide collaborative effort to better understand what goes wrong with synapses in neurodegenerative disease
- Transcriptomics and proteomics - a UK DRI-wide collaborative effort to develop and implement single cell and spatial-omics approaches to better understand why a disease starts and the consequences of pathological protein accumulation on cellular pathways
Beyond UK DRI:
- Multi-lab, multi-institution project to understand the relationship between tauopathy spread in the hippocampal formation and deficits in spatial navigation, in mouse models and humans with Alzheimer's disease
- Multi-lab, multi-institution project to identify the role of genetic modifiers and risk factors in disease diversity
- Prof Selina Wray, UCL - enhance capability to generate human cell models of degenerative disease
Tau and tauopathy, amyloid, Alzheimer’s disease (AD), Frontotemporal dementia (FTD), ageing, pathogenesis, functional decline, cognitive impairment, neurodegeneration, cellular molecular signatures, network dysfunction, mouse models, functional imaging, structural analysis, genetic analysis
Spatial and single cell transcriptomics and proteomics, mass cytometry, mass spectroscopy, flow cytometry, light microscopy, electron microscopy, genetic analysis, immunohistochemistry, quantitative immunoblotting, ELISA, protein detection using Simoa, cell biology, computational biology, bioinformatics, differential expression analysis, cognitive testing, in vivo electrophysiology
7. Key publications
Ari W. Schaler, Avery M. Runyan, Stephanie L. Fowler, Helen Y. Figueroa, Seiji Shioda, Ismael Santa-Maria, Karen E. Duff, Natura Myeku (2021). PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain. Sci Transl Med. 2021 May 26;13(595): eaba7394. DOI:10.1126/scitranslmed.aba7394.
Fu H, Possenti A, Freer R, Nakano Y, Villegas NCH, Tang M, Cauhy PVM, Lassus BA, Chen S, Fowler SL, Figueroa HY, Huey ED, Johnson GVW, Vendruscolo M, Duff KE. A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology Nature Neurosci. 2019 Jan; 22 (1):47-56. DOI: 10.1038/s41593-018-0298-7.
Fu H, Rodriguez G, Herman M, Emrani S, Nahmani E, Figueroa HY, Goldberg E, Hussaini S. A and Duff K.E (2017). Tau Pathology Induces Excitatory Neuron Loss, Grid Cell Dysfunction and Spatial Memory Deficits Reminiscent of Early Alzheimer's Disease. Neuron 93, 3, p533–541. DOI: 10.1016/j.neuron.2016.12.023.
Wu J.W., Hussaini S-A., Bastille I., Rodriguez G., Mrejeru A., Rilett K., Sanders D., Cook C., Fu, H.,Boonen R.A., Herman M., Nahmani E., Emrani S., Figueroa Y.H., Diamond M., Clelland C.L., Wray S. and Duff K.E. (2016) Neuronal activity enhances tau propagation and tau pathology in vivo Nat. Neuro 19(8):1085-92. DOI: 10.1038/nn.4328.
Myeku N., Clelland CL., Emrani S., Kukushkin N.V., Yu W.H., Goldberg A.L and Duff K.E (2016) Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP- PKA signaling. Nature. Medicine. 22(1):46-53. DOI: 10.1038/nm.4011.